Clearance Summary
DIRECT BILIRUBIN received FDA 510(k) clearance under submission number K022180, sponsored by Abbott Laboratories. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2002-09-06.
- Submission: K022180
- Applicant / Sponsor: Abbott Laboratories
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class II
- Regulation citation: 21 CFR 862.1110
- Decision date: 2002-09-06
Classification & Regulation
This clearance is catalogued under FDA product code CIG and 21 CFR 862.1110, within the Clinical Chemistry review panel as a Class II device.